Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: Bridging the knowledge gap to end the pandemic for organ transplant recipients.
作者信息
Haidar Ghady
机构信息
Division of Infectious Diseases, University of Pittsburgh and UPMC, Pittsburgh, Pennsylvania.
出版信息
J Heart Lung Transplant. 2022 Oct;41(10):1426-1428. doi: 10.1016/j.healun.2022.07.004. Epub 2022 Jul 11.
Abstract
摘要
相似文献
1
Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: Bridging the knowledge gap to end the pandemic for organ transplant recipients.心脏移植后对第三剂BNT162B2新冠疫苗的免疫：弥合知识差距以终结器官移植受者的大流行。
J Heart Lung Transplant. 2022 Oct;41(10):1426-1428. doi: 10.1016/j.healun.2022.07.004. Epub 2022 Jul 11.
2
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence.心脏移植受者六个月内对第三剂BNT162B2新冠疫苗的细胞和体液反应动力学——对奥密克戎变种的启示：通信
J Heart Lung Transplant. 2022 Nov;41(11):1649-1650. doi: 10.1016/j.healun.2022.07.012. Epub 2022 Jul 22.
3
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2疫苗在实体器官移植受者中的免疫原性。
Am J Transplant. 2021 Aug;21(8):2913-2915. doi: 10.1111/ajt.16607. Epub 2021 May 7.
4
Seroconversions After Withdrawal From Mycophenolate Mofetil in Solid Organ Transplant Recipients Without a Third Dose of BNT162b2 mRNA Coronavirus Disease 2019 Vaccine: A Case Series.实体器官移植受者停用吗替麦考酚酯后在未接种第三剂BNT162b2 mRNA新型冠状病毒肺炎疫苗情况下的血清学转换：病例系列
Transplantation. 2022 Apr 1;106(4):e238-e239. doi: 10.1097/TP.0000000000004043.
5
Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者中灭活 SARS-CoV-2 疫苗和 BNT162b2 mRNA 疫苗的抗体反应差异。
Exp Clin Transplant. 2021 Dec;19(12):1334-1340. doi: 10.6002/ect.2021.0402.
6
Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.在一组多样化的实体器官移植候选人和受者中，两剂严重急性呼吸综合征冠状病毒 2 疫苗的早期体液免疫反应。
Clin Transplant. 2022 May;36(5):e14600. doi: 10.1111/ctr.14600. Epub 2022 Feb 2.
7
Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months.心脏移植受者在6个月以上对BNT162b2疫苗的体液免疫反应减弱。
Am J Transplant. 2022 Jul;22(7):1931-1932. doi: 10.1111/ajt.16998. Epub 2022 Mar 1.
8
Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses.在接受两剂BNT162b2后血清学阴性的实体器官移植受者中，与BNT162b2相比，mRNA-1273作为第三剂疫苗可提高体液免疫原性。
Clin Transplant. 2022 Aug;36(8):e14738. doi: 10.1111/ctr.14738. Epub 2022 Jun 14.
9
Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients.第三剂 BNT162b2 mRNA 疫苗在心脏移植受者中的免疫原性增强。
Eur J Cardiothorac Surg. 2022 Sep 2;62(4). doi: 10.1093/ejcts/ezac145.
10
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.血液系统疾病患者和器官移植受者对 BNT162b2 疫苗的体液反应比较分析。
Transpl Immunol. 2022 Dec;75:101713. doi: 10.1016/j.trim.2022.101713. Epub 2022 Sep 12.
引用本文的文献
1
COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence.实体器官移植受者的 COVID-19 预防：现有证据状况。
Infect Dis Clin North Am. 2023 Sep;37(3):459-473. doi: 10.1016/j.idc.2023.03.002. Epub 2023 Mar 22.
本文引用的文献
1
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体BA.2.12.1、BA.4和BA.5的中和逃逸
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.
2
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.心脏移植受者接种第三剂 BNT162B2 疫苗后 6 个月内细胞和体液反应的动力学——对奥密克戎变异株的影响。
J Heart Lung Transplant. 2022 Oct;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014. Epub 2022 May 24.
3
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients.肾移植受者对三剂、四剂和五剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应
J Clin Med. 2022 May 4;11(9):2565. doi: 10.3390/jcm11092565.
4
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442（替沙格韦单抗-西加韦单抗）预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
5
A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response.四剂 COVID-19 疫苗不能诱导对奥密克戎变异株的中和反应，而在对疫苗反应不佳的实体器官移植受者中。
Transplantation. 2022 Jul 1;106(7):1440-1444. doi: 10.1097/TP.0000000000004140. Epub 2022 Apr 4.
6
Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients.临时抗代谢药物治疗暂停可增强肾移植受者中针对 SARS-CoV-2 疫苗的体液和细胞免疫。
JCI Insight. 2022 May 9;7(9):e157836. doi: 10.1172/jci.insight.157836.
7
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).广泛免疫抑制人群中新型冠状病毒病 2019（COVID-19）疫苗反应的前瞻性评估：免疫抑制人群中的 COVID-19 疫苗接种研究（COVICS）。
Clin Infect Dis. 2022 Aug 24;75(1):e630-e644. doi: 10.1093/cid/ciac103.
8
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.mRNA 新冠疫苗 2 剂接种对免疫功能低下成人因 COVID-19 住院的效果-9 个州，2021 年 1 月至 9 月。
MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559. doi: 10.15585/mmwr.mm7044e3.
9
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.心脏移植受者接种 BNT162b2 疫苗的第三剂：免疫原性和临床经验。
J Heart Lung Transplant. 2022 Feb;41(2):148-157. doi: 10.1016/j.healun.2021.08.010. Epub 2021 Aug 28.
10
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.移植受者中第三剂mRNA-1273疫苗的随机试验。
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
Zotero 插件